The Research of Operating Conditions of FDA Sentinel Initiative and Enlightenment

Abstract

Abstract: Objective To introduce FDA sentinel initiative operation action to provide a reference for our medical product safety monitoring. Methods By analyzing the background, characteristics of sentinel initiative, the organizational framework, the specific operation, and safety assessment process of Mini-sentinel which is a pilot of sentinel initiative, put forwarda security monitoring method suited to our national conditions. Results & Conclusion Based on passive monitoring of existing medical products, actively carry out an active surveillance. Through a combination of medicare data systems and electronic medical records system, integrate existing electronic data resources for query and analysis of the safety monitoring data, at the same time develop new data management Methods to improve the data processing and analysis capabilities.

Key words: FDA, sentinel initiative, active surveillance, enlightenment

CLC Number:

R181.35

BIAN Lei ,ZHAO Pin, YANG Yue. The Research of Operating Conditions of FDA Sentinel Initiative and Enlightenment [J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 25-29.

References

[1] FDA.The Sentinel Initiative [EB/OL].http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM233360.pdf,2010-06.
[2] Harvard Pilgrim Health Care. About us[N/OL].https://www.harvardpilgrim.org/portal/page_pageid=213 , 49561&_dad=portal&_schema=PORTAL,2012-11-10.
[3] FDA.FDA Awards Contract to Harvard Pilgrim to Develop Pilotfor SafetyMonitoringSystem[N/OL].http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm196968.htm,2011-1-8.
[4] 医药经济报.FDA如何做到保持世界最高安全监测标准[N/OL].http://www.winpharm.net/conewsshow.aspid=4826&jdfwkey=ts2d01,2012-7-24.
[5] Richard Platt.FDA's Mini-Sentinel Program to Evaluate the Safetyof Marketed Medical Products [R/OL].http://www.mini-sentinel.org/work_products/Publications/Mini-Sentinel_Progress-and-Direction.pdf, 2012-1-18.
[6] Susan Forrow, Daniel M. Campion, Lisa J,etc. The organizational structure and governing principles of the Food and Drug Administration'sMini-Sentinel pilot program[J]. PHARMACOEPIDEMIOLOGYAND DRUG SAFETY,2012,21(S1):12-17.
[7] Deven McGraw, Kristen Rosati ,Barbara Evans, etc. A policy framework for public health uses of electronic health data [J].PHARMACOEPIDEMIOLOGY AND DRUG SAFETY,2012, 21(S1):18-22.
[8] Mini Sentinel. Overview and Description of the Common Data Model v2.1[R/OL].http://www.mini-sentinel.org/work_products/Data_Activities/Mini-Sentinel_Common-Data-Model_v2.1.pdf,2012-1-18.
[9] Richard Platt, Ryan M, Carnahan,etc. The U.S. Food and Drug Administration's Mini-Sentinel program:status and direction [J].PHARMACOEPIDEMIOLOGY AND DRUG SAFETY,2012,21
(S1):1-8.
[10] FDA.The Sentinel Initiative[EB/OL]. http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM233360.pdf, 2010-06.
[11] 沈璐,刘巍,范燕,等.论我国药品不良反应监测技术工作的发展阶段[J].中国药物警戒,2012,9(3):146-149.
[12] 邹琛.试论我国开展药品主动监测的策略[J].药物流行病学杂志,2011,20(4):209-211.
[13] 人民网.我国参与基本医疗保险覆盖率超过95%[N/OL].http://finance.people.com.cn/insurance/h/2012/0209/c227929-1110887107.
html, 2012-2-9.

[1]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[2]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[3]	ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing. Advances in studies on post-market safety data sources and signal detection for medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
[4]	HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua. Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
[5]	WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
[6]	SUN Yixin, LIU Zhike, ZHAN Siyan. Scoping review of near real-time surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
[7]	LIU Zhike, ZHAN Siyan. Progress in applications of self-controlled designs in association study of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
[8]	REN Yuqin, LI Xin, YU Min, SU Yuwen. Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
[9]	ZHANG Chi. Data mining of adverse drug events of alirocumab from openFDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
[10]	CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi. Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
[11]	ZHAO Xiaohong, GUO Mingxing, WANG Xiaojian, LIN Jianrui, CUI Xiangli. Risk signal mining related to lenvatinib based on the US FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1233-1237.
[12]	SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu. Research and reflection on regulatory science developments of U.S. FDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
[13]	LING Tao, XU Ruijuan, GE Weihong. Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 780-783.
[14]	WEI Fuqian, ZHANG Wei, YANG Yue. Drug Risk Communication between Drug Regulatory Agencies and the Public [J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 949-952.
[15]	LI Jiangfan, HU Ye, PANG Hongxian, ZHAO Dan, LI Xinru, WANG Xuhong. Comparative Analysis of Adverse Drug Reactions of Evolocumab and Alirocumab Based on OpenFDA [J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 965-968.